Sulfonylureas are a class of oral medications used to treat type 2 diabetes, including glibenclamide (glyburide), gliclazide, glimepiride, and glipizide. They have been used for decades and remain widely prescribed, particularly where cost is a major factor in treatment choice, though current guidelines increasingly favor other drug classes as second-line options after metformin due to newer safety and cardiovascular data.
Sulfonylureas work by binding to the SUR1 (sulfonylurea receptor 1) subunit of the KATP (ATP-sensitive potassium) channel on the surface of pancreatic beta cells. This binding causes the channel to close. Because the channel normally allows potassium to leave the cell, closing it causes potassium to build up inside, which depolarizes the cell membrane. This depolarization opens voltage-gated calcium channels, allowing calcium to flow into the cell. The rise in intracellular calcium triggers the beta cell to release stored insulin from its vesicles into the bloodstream. In short, sulfonylureas force the beta cell to release insulin regardless of the current blood sugar level — which is both their main benefit and the root of their main risk.
Sulfonylureas are effective at lowering blood glucose, typically reducing HbA1c by about 1 to 2 percentage points, an effect comparable to many newer drug classes. They act quickly, often improving blood sugar within days of starting treatment. They are also inexpensive and widely available, which makes them an important option in settings where cost is a barrier to newer medications such as SGLT2 inhibitors or GLP-1 receptor agonists.
1, The most common and important side effect is hypoglycemia (low blood sugar), a direct consequence of the drug’s mechanism: because sulfonylureas force insulin release regardless of blood glucose level, they can trigger insulin release even when blood sugar is already normal or low, particularly if a meal is delayed or skipped. This risk is higher with longer-acting sulfonylureas such as glibenclamide, and higher still in older adults and those with kidney impairment, who clear the drug from their body more slowly.
2,
Sulfonylureas require caution in several situations. In people with reduced kidney function, the drug clears more slowly and can accumulate, increasing hypoglycemia risk — many sulfonylureas need dose reduction or should be avoided once kidney function (GFR) falls below 60 mL/min, and glibenclamide in particular is not recommended once GFR falls below 50 mL/min. Older adults are at higher risk of hypoglycemia and may have symptoms that are harder to recognize, so lower starting doses are generally used. Food and medication timing should be well matched — skipping or delaying meals after taking a sulfonylurea raises the risk of a low blood sugar episode. People with a known sulfa allergy should discuss this with their doctor before starting, as some sulfonylureas share a chemical structure with sulfa antibiotics. Alcohol can increase the risk and severity of hypoglycemia and should be used cautiously.
1. Patel S, Yan Z, Remedi MS. "Loss of Beta-Cell Identity and Function as a Mechanism of Secondary Failure of Sulfonylurea Therapy in Diabetes." MedComm, 2026;7:e70588. DOI: 10.1002/mco2.70588 (mouse model — KK-Glib mice)
2. Remedi MS, Nichols CG. "Chronic Antidiabetic Sulfonylureas In Vivo: Reversible Effects on Mouse Pancreatic β-Cells." PLOS Medicine, 2008;5(10):e206. DOI: 10.1371/journal.pmed.0050206
3. American Diabetes Association. "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026." Diabetes Care. pmc.ncbi.nlm.nih.gov/articles/PMC12690185/
4. Sola D, et al. "Sulfonylureas and Their Use in Clinical Practice." StatPearls [Internet]. NCBI Bookshelf, NBK513225. ncbi.nlm.nih.gov/books/NBK513225
Editorial note for reviewer: the two sulfonylurea mechanistic sources above (Patel 2026 and Remedi/Nichols 2008) are both animal-model (mouse) studies. The article text describes them as such and notes that the 2026 finding needs human confirmation — please verify this framing is precise enough before publishing, and adjust if newer human data has since emerged.
This article has been published by the Healthnep editorial team for general information and educational purposes only. The author is not a licensed medical doctor or professional healthcare practitioner. The content provided here does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified health provider regarding any medical condition or before starting any new treatment. Never disregard professional medical advice or delay seeking it because of something you have read on this platform.
What Are SGLT2 Inhibitors?SGLT2 इनहिबिटर के हो?SGLT2 inhibitors ar...
Read More